ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.691,32
0,05%
S&P 500
5.310,95
0,07%
Dow Jones
39.335,43
-0,85%
Euro vs US Dollar
1,08255
0,00%
Bitcoin
67.839,05
-1,83%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Tourmaline Bio Inc (TRML)

  7. Tourmaline Bio Inc (TRML) News

TRML

Tourmaline Bio (TRML)

Tourmaline Bio Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TRML
DatumZeitQuelleÜberschriftSymbolFirma
23/05/202413h10GlobeNewswire Inc.Tourmaline Bio to Present at the Jefferies Global Healthcare ConferenceNASDAQ:TRMLTourmaline Bio Inc
16/05/202413h00GlobeNewswire Inc.Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY TrialNASDAQ:TRMLTourmaline Bio Inc
13/05/202422h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TRMLTourmaline Bio Inc
13/05/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
13/05/202413h00GlobeNewswire Inc.Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:TRMLTourmaline Bio Inc
02/04/202413h00GlobeNewswire Inc.Avalo Therapeutics Appoints Biotech Leaders to Board of DirectorsNASDAQ:TRMLTourmaline Bio Inc
19/03/202412h00GlobeNewswire Inc.Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:TRMLTourmaline Bio Inc
27/02/202413h30GlobeNewswire Inc.Tourmaline Bio to Present at Upcoming Investor ConferencesNASDAQ:TRMLTourmaline Bio Inc
15/02/202403h08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TRMLTourmaline Bio Inc
15/02/202402h51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TRMLTourmaline Bio Inc
09/02/202422h22Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TRMLTourmaline Bio Inc
01/02/202414h00GlobeNewswire Inc.Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:TRMLTourmaline Bio Inc
29/01/202422h01GlobeNewswire Inc.Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:TRMLTourmaline Bio Inc
26/01/202422h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
26/01/202422h08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TRMLTourmaline Bio Inc
25/01/202413h00GlobeNewswire Inc.Tourmaline Bio Announces Pricing of Public Offering of Common StockNASDAQ:TRMLTourmaline Bio Inc
25/01/202403h20Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TRMLTourmaline Bio Inc
24/01/202423h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
24/01/202422h05GlobeNewswire Inc.Tourmaline Bio Announces Proposed Public Offering of Common StockNASDAQ:TRMLTourmaline Bio Inc
08/01/202415h19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
08/01/202413h00GlobeNewswire Inc.Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)NASDAQ:TRMLTourmaline Bio Inc
15/12/202322h00GlobeNewswire Inc.Tourmaline Bio added to the NASDAQ Biotechnology IndexNASDAQ:TRMLTourmaline Bio Inc
14/12/202314h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
14/12/202313h30GlobeNewswire Inc.Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the BoardNASDAQ:TRMLTourmaline Bio Inc
30/11/202314h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
01/11/202313h00GlobeNewswire Inc.Tourmaline Bio to Present at Upcoming Investor ConferencesNASDAQ:TRMLTourmaline Bio Inc
24/10/202302h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRMLTourmaline Bio Inc
24/10/202302h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRMLTourmaline Bio Inc
24/10/202302h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRMLTourmaline Bio Inc
24/10/202302h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRMLTourmaline Bio Inc
 Showing the most relevant articles for your search:NASDAQ:TRML

Kürzlich von Ihnen besucht

COIN
ASWUST
Wrapped AdaSwap
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten